Data Supplement from Discordant <i>In Vitro</i> and <i>In Vivo</i> Chemopotentiating Effects of the PARP Inhibitor Veliparib in Temozolomide-Sensitive versus -Resistant Glioblastoma Multiforme Xenografts

<p>Supplementary Figure S6. Measurements of tumor growth after treatment with veliparib, TMZ or their combination in TMZ-sensitive versus resistant GBM models in vivo.</p>